Vitamin-Like supplement tested for diabetic nerve pain – but trial stopped early
NCT ID NCT03685253
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested whether nicotinamide riboside (a form of vitamin B3 sold as Niagen) could help repair nerve damage in people with type 2 diabetes or prediabetes. Only 10 participants were enrolled before the study was terminated. The main goal was to measure changes in nerve fiber density in the skin. Because the trial was small and stopped early, it's unclear if this supplement offers any benefit for diabetic neuropathy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Nicotinamide riboside (Niagen)
- What this could lead to
- If it works, this could point toward a treatment for diabetic nerve damage by helping restore nerve fibers.
- What could go wrong
- This was a very small, early-phase trial that was terminated, so we don't have clear evidence it works. The supplement may not improve nerve health in people with diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC NEUROPATHY PERIPHERAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Maryland
Baltimore, Maryland, 21201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.